tiprankstipranks
Advertisement
Advertisement
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
PremiumThe FlyIntellia Therapeutics price target raised to $17 from $12 at Wedbush
11d ago
Alnylam price target raised to $468 from $420 at Raymond James
Premium
The Fly
Alnylam price target raised to $468 from $420 at Raymond James
12d ago
Alnylam: TTR Growth In Line With Expectations Keeps Risk-Reward Balanced and Price Target Unchanged at $370
Premium
Ratings
Alnylam: TTR Growth In Line With Expectations Keeps Risk-Reward Balanced and Price Target Unchanged at $370
21d ago
Analyst Reiterates Buy on Alnylam, Maintains $510 Price Target on Pipeline and Growth Optionality
PremiumRatingsAnalyst Reiterates Buy on Alnylam, Maintains $510 Price Target on Pipeline and Growth Optionality
27d ago
Alnylam: Hold Rating Reaffirmed as TTR Franchise Growth Offsets Slight Sales Shortfall; $370 Price Target Unchanged
Premium
Ratings
Alnylam: Hold Rating Reaffirmed as TTR Franchise Growth Offsets Slight Sales Shortfall; $370 Price Target Unchanged
1M ago
Alnylam management to meet with Oppenheimer
Premium
The Fly
Alnylam management to meet with Oppenheimer
1M ago
Alnylam Shareholders Reaffirm Board, Pay Practices and Auditor
PremiumCompany AnnouncementsAlnylam Shareholders Reaffirm Board, Pay Practices and Auditor
2M ago
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
Premium
The Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
2M ago
Alnylam initiated with a Buy at Citi
Premium
The Fly
Alnylam initiated with a Buy at Citi
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100